Sartorius Stedim Biotech
Investors Presentation
H1 2021 Results
This presentation contains statements concerning the future performance of the Sartorius Stedim Biotech Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements. Throughout this presentation, differences may be apparent as a result of rounding during addition.
Agenda

Overview | Strategy

Mid-term Growth Prospects

H1 2021 Results | FY 2021 Guidance

Appendix
A leading partner of the biopharma industry

We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and more affordable medicine.

The United Nations’ sustainability goal ‘Good Health and Well-Being’ is thus an integral part of our core business.
Sartorius Stedim Biotech at a glance

€ ~€1.9bn
Sales revenue 2020

~16.5%
Sales CAGR¹ 2015-2020

~31.7%
EBITDA margin² 2020

>20
countries, headquartered in Aubagne, France

> 7,500
Employees

Four strong pillars drive above-average growth

Pharma market → CAGR 4-7%

Biopharma market → CAGR ~10%

Single-use penetration → Double-digit growth

Market share gains → Esp. in North America

¹ In constant currencies  ² Excluding extraordinary items
Covering most steps of the biopharmaceutical manufacturing process

- Differentiated by the range and completeness of the portfolio
- Excellent positioning in key single-use technologies
- Internationally recognized supplier enabling innovation in bioprocessing through own R&D and partnerships
Generating revenue throughout the lifecycle of a biopharma drug

- Wide product range of equipment and consumables for all stages (from pre-commercial to large-scale manufacturing); optimal scalability
- Engineering support with excellent application knowhow and understanding of the entire bio-production process
- Production process of each individual drug is subject to validation by health authorities (e.g. FDA, EMA) and part of the drug approval
Integrated services and technologies for all types of biopharmaceuticals

- ~95% of revenue generated with bio/pharma customers
- Antibodies are most relevant; strong position in vaccines as well
- SSB provides solutions for the development and production of all biotechnologically derived drugs and cell derivatives
- These also include new modalities such as cell and gene therapies and viral vectors
The market landscape is dynamic across therapy modalities

<table>
<thead>
<tr>
<th>Protein-based therapies</th>
<th>Viral-based therapies</th>
<th>Advanced therapies</th>
</tr>
</thead>
<tbody>
<tr>
<td>• mAbs</td>
<td>• Viral vectors for gene therapy</td>
<td>• Cell therapy (e.g., iPSC, MSC)</td>
</tr>
<tr>
<td>• Bi-/Multi-specifics</td>
<td>• Virus and viral vector vaccines</td>
<td>• Gene-modified cell therapy (CAR-T)</td>
</tr>
<tr>
<td>• Bioconjugates</td>
<td>• Oncolytic viruses</td>
<td></td>
</tr>
<tr>
<td>• Recombinant proteins and peptides</td>
<td>• Novel modalities (e.g., mRNA, DNA, Exosomes)</td>
<td></td>
</tr>
<tr>
<td>• Protein-based vaccines</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

65% 20% 15%

Share of molecules in R&D pipeline; source: Global Data, March 2021

Overview | Strategy
Attractive market environment offers strong growth opportunities

Growing and aging population
9 billion people by 2050

World population over age 60 in 2050
>2bn

World population over 60 in 2020
~1bn

Biologics are gaining importance
Share of biologics in pharma end market

Sales share of biologics in 2026
~35%

Sales share of biologics in 2020
~30%

~10% CAGR
for the biopharma market in 2020 – 2025
Sales revenue more than doubled over the last 5 years

Sales CAGR ~+16%
EBITDA margin +10.8pp

~€477m to ~€884m

~€1.9bn

Sales growth and CAGR in constant currencies 1 Excluding extraordinary items
Regionalizing our supply chain and manufacturing; increasing our global capacity

**Germany | Göttingen, Guxhagen**
Production capacities increasing

**China and South Korea**
Capacities will be created in selected areas

**Puerto Rico and USA**
Capacities will be ramped up for selected areas

- Separation
- Instruments and systems
- Separation
- Fluid management
- Cell culture media
- Cell culture media
- Fluid management
- Customer interaction
M&A strategy – adding innovation, enhancing focus

Acquisition criteria

- **Portfolio**: Complementary products or technologies
- **Market position**: Either among the Top 3 or unique selling point
- **Integration**: Management capacity; cultural fit
- **Price**: Fair valuation; reach Sartorius’ profitability level in 2-3 years

1. Acquired from Danaher
Recent acquisitions strengthen portfolio...

Acquisition of selected life science assets from Danaher

- Portfolio of upstream and downstream technologies

- ~$275m Purchase price
- ~$100m Sales revenue in 2019
- + 100 Employees
- May 2020 Date of consolidation

Acquisition of BIA Separations

- Technology for purification in advanced therapy processes

- €360mn Purchase price
- ~€25m Sales revenue in 2020e
- + 120 Employees
- Nov. 2020 Date of consolidation
Acquisition of WaterSep BioSeparations

- Innovative hollow fiber crossflow filtration units
- Purchase price $27mn plus earn-out

Agreement to acquire chromatography process equipment division from Novasep

- Resin-based batch and intensified chromatography systems
- Purchase price not disclosed

~$2.5m
Sales revenue in 2020e

+15
Employees

Dec. 2020
Date of consolidation

~€37m
Sales revenue in 2020e

+100
Employees

H1 2021
Closing expected
BIA Separations - Bioprocessing innovator, addressing bottlenecks in advanced therapies

Ajdovščina, Slovenia
~120 employees
Quadrupling production capacity till end 2021
Acquired November 2020

Portfolio
- Pre-packed monolithic columns optimized for purification in advanced therapy processes (e.g. viruses, plasmids, exosomes)
- Provides significantly higher yield by avoiding shearing effects which occur in traditional purification processes, e.g. in chromatography

Positioning
- Monoliths already used in production of first commercialized advanced therapeutics
- Strong presence in (pre-) clinical projects

Monolithic columns
WaterSep BioSeparations – Further broadening our filtration portfolio

Marlborough, USA
~15 employees
R&D and production of membranes and cartridges
Acquired December 2020

Hollow fiber cartridges

Portfolio
- Hollow-fiber membrane devices and pre-sterilized assemblies for crossflow filtration applications in upstream and downstream
- Addresses customer needs for cost- and time-saving solutions

Strategic fit
- Complements offering for cell and gene therapy applications, cell harvesting and various solutions for intensified bioprocessing
## Competitive portfolio across our relevant end-markets

<table>
<thead>
<tr>
<th>SSB</th>
<th>Merck</th>
<th>Millipore</th>
<th>Danaher</th>
<th>Cytiva</th>
<th>Thermo Fisher</th>
<th>Top 3 Players</th>
</tr>
</thead>
</table>
| Filtration | ![Filtration Chart](chart1) | ![Filtration Chart](chart1) | ![Filtration Chart](chart1) | ![Filtration Chart](chart1) | ![Filtration Chart](chart1) | 1. Merck | Millipore  
2. Danaher | Pall  
3. Sartorius Stedim Biotech |
| Fluid Management | ![Fluid Management Chart](chart2) | ![Fluid Management Chart](chart2) | ![Fluid Management Chart](chart2) | ![Fluid Management Chart](chart2) | ![Fluid Management Chart](chart2) | 1. Sartorius Stedim Biotech  
2. Thermo Fisher  
3. Merck | Millipore |
| Fermentation | ![Fermentation Chart](chart3) | ![Fermentation Chart](chart3) | ![Fermentation Chart](chart3) | ![Fermentation Chart](chart3) | ![Fermentation Chart](chart3) | 1. Sartorius Stedim Biotech  
2. Thermo Fisher  
3. Danaher | Cytiva |
| Purification | ![Purification Chart](chart4) | ![Purification Chart](chart4) | ![Purification Chart](chart4) | ![Purification Chart](chart4) | ![Purification Chart](chart4) | 1. Danaher | Cytiva  
2. Merck | Millipore  
3. Sartorius Stedim Biotech |
| Cell Culture Media | ![Cell Culture Media Chart](chart5) | ![Cell Culture Media Chart](chart5) | ![Cell Culture Media Chart](chart5) | ![Cell Culture Media Chart](chart5) | ![Cell Culture Media Chart](chart5) | 1. Thermo Fisher  
2. Merck | Millipore  
3. Danaher | Cytiva |

1 Formerly GE Biopharma

Pie charts indicate completeness of product offering
Pioneer and leader in the growing single-use technology market

Single-use market penetration expected to increase from ~35% to ~75%

Single-use products offer advantages over conventional stainless-steel devices

- Capex|Opex reduction over entire lifecycle
- Reduced risk of cross-contamination
- Higher flexibility; advantageous for biosimilars

<table>
<thead>
<tr>
<th></th>
<th>Construction cost</th>
<th>Time-to-market</th>
<th>Energy cost</th>
<th>Water cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reference</td>
<td>-25-35%</td>
<td>-30-50%</td>
<td>-55-65%</td>
<td>-65-75%</td>
</tr>
<tr>
<td>Single-use</td>
<td>-30-50%</td>
<td></td>
<td>-55-65%</td>
<td>-65-75%</td>
</tr>
</tbody>
</table>
Single-use allows manufacturers to mitigate investment risks

- Construction of stainless-steel based facilities takes longer and is more complex compared to single-use
- Therefore, investment in stainless-steel facilities has to start in early clinical phase II
- The construction of single-use facilities may start in clinical phase III, reducing investment risks of our clients

<table>
<thead>
<tr>
<th>Clinical Phase I</th>
<th>Clinical Phase II</th>
<th>Clinical Phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Probability that candidate advances to next stage</td>
<td>~ 60%</td>
<td>~ 30%</td>
</tr>
<tr>
<td>Probability of approval</td>
<td>~ 10%</td>
<td>~ 15%</td>
</tr>
</tbody>
</table>

Data based on: Wong et al. (2018): Estimation of clinical trial success rates and related parameters
Limited dependence on individual accounts

Long-term business relationships with leading global (bio-) pharma companies

- More than half of 2020 sales were generated with the Top 50 customers
- No individual customer accounts for more than 5% of sales revenue
Our products are widely used in the development and production of biologics against COVID-19

We helped our customers to manage extremely challenging development timelines and to ease scaling of vaccine processes all the way to commercialization

- Education on SUT processes
- Delivery of key products across vaccine modalities (viral vectors, mRNA, proteins) and Covid-19 therapeutics
- Joint development of solutions with our application expertise

Vaccine development acceleration here to stay

- mRNA validated
- New technologies in manufacturing; capacity and technology decisions established
- Pace of development

Pandemic effects in 2020

- Pandemic-related net effect of a good ~12pp on sales revenue and close to ~19pp on order intake growth; consisting of investments in vaccine and therapeutic research and manufacturing, also inventory build-up
Agenda

Overview | Strategy

Mid-term Growth Prospects

H1 2021 Results | FY 2021 Guidance

Appendix
2025 ambition – increased baseline and organic growth

- Initial 2025 group sales revenue targets were based on an estimated 2020 group revenue of €1.5 to 1.6bn, based on the mid-term guidance of 2012
- Actual 2020 Group revenue was approx. €1.9bn
- New mid-term target reflects both the elevated baseline and future growth prospects
- Continued strategy is to achieve the targets primarily through organic growth; acquisition to contribute underproportionally
- The increase in the profitability outlook is due to economies of scale and also reflects the assumption of acquisitions to be initially dilutive

<table>
<thead>
<tr>
<th></th>
<th>Sartorius Stedim Biotech</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales revenue</td>
<td>€4bn</td>
</tr>
<tr>
<td>previously</td>
<td>~€2.8bn</td>
</tr>
<tr>
<td>EBITDA margin</td>
<td>~33%</td>
</tr>
<tr>
<td>previously</td>
<td>~30%</td>
</tr>
</tbody>
</table>

2025 targets are based on 2020 currency exchange rates; EBITDA excluding extraordinary items
U.S. remains most important market; China with highest growth rates

Biologics market growth forecast

- **2020**: €250bn
  - U.S.: ~119
  - Europe: ~46
  - China: ~38
  - ROW: ~47

- **2024**: €365bn
  - U.S.: ~167
  - Europe: ~58
  - China: ~67
  - ROW: ~72

CAGR:
- ~+9% U.S.
- ~+6% Europe
- ~+15% China

Sartorius Stedim Biotech
The Chinese market is in the next development phase

Dynamic increase in new biopharma companies

Source: BCG, Sartorius

Increasingly focusing on innovative medicines

China’s activity as a percentage of global activity

Innovation 2.0
Biologics innovators, indication expansion, technology modification

Innovation 3.0
New modalities/New MOAs

Source: BCG, Sartorius
Regional balance better reflecting end-markets

Sales by region 2011:
- Asia | Pacific: 20%
- Americas: 27%
- EMEA: 53%

CAGR (Compound Annual Growth Rate) for continued operations, in constant currencies:
- Asia | Pacific: ~+16%
- Americas: ~+18%
- EMEA: ~+11%

Sales by region 2020:
- Asia | Pacific: 25%
- Americas: 35%
- EMEA: 40%

Global biopharma market 2019:
- Asia | Pacific: 28%
- Americas: 50%
- EMEA: 22%

CAGR for continued operations, in constant currencies.
Biosimilars: Strong growth, big opportunities

- Major blockbuster biologics are going off-patent
- Time-to-market is key as only the first providers are most likely profitable
- Several approvals in Asia and Europe; U.S. at the beginning
- For now, relatively small market but with strong growth
- Single-use is the preferred platform for biosimilars

Biosimilars will outperform the biologics market
€ in billions

- ~235.5
- ~14.5
- ~41.5
- ~323.5

Growing number of biosimilar approvals
E.U. and U.S.

- 2012: 0
- 2013: 0
- 2014: 3
- 2015: 1
- 2016: 7
- 2017: 22
- 2018: 20
- 2019: 15
- 2020: 16

CAGR: ~+30%
High innovation dynamics in Biopharma

Development of new drugs and vaccines must be accelerated, e.g. through more automation.

Increased efficiency possible in the production of 'classic' biopharmaceuticals and biosimilars.

New tools and methods required e.g. for novel cell and gene therapies.

Future drug manufacturing is more automated, intensified and scalable.
Analytical technologies to improve process economics and safety

- Bioprocess sensors, analyzers and software
- Collect, monitor and control quality-critical parameters
- Analyze data to obtain a better process understanding
- Use knowledge for process development, optimization and automation
- Allows customers to increase time-to-market, to reduce COGS, to improve process robustness and product quality
- Intention to upgrade Umetrics software suite with advanced analytics technologies such as AI and machine learning
- Data analytics just at the beginning in biomanufacturing with high potential
Agenda

Overview | Strategy
Mid-term Growth Prospects
H1 2021 Results | FY 2021 Guidance
Appendix
Exceptionally strong and profitable growth in H1 2021

<table>
<thead>
<tr>
<th>Sartorius Stedim Biotech Group</th>
<th>H1 2020</th>
<th>H1 2021</th>
<th>▲ in %</th>
<th>▲ in % cc&lt;sup&gt;1&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales revenue</td>
<td>869.1</td>
<td>1,351.9</td>
<td>+55.6</td>
<td>+61.1</td>
</tr>
<tr>
<td>Order intake</td>
<td>1,048.7</td>
<td>1,889.9</td>
<td>+80.2</td>
<td>+87.4</td>
</tr>
<tr>
<td>Underlying EBITDA&lt;sup&gt;2&lt;/sup&gt;</td>
<td>262.3</td>
<td>487.4</td>
<td>+85.8</td>
<td></td>
</tr>
<tr>
<td>Underlying EBITDA&lt;sup&gt;2&lt;/sup&gt; margin in %</td>
<td>30.2</td>
<td>36.1</td>
<td>+5.9pp</td>
<td></td>
</tr>
<tr>
<td>Underlying EPS&lt;sup&gt;3&lt;/sup&gt; in €</td>
<td>1.82</td>
<td>3.49</td>
<td>+91.9</td>
<td></td>
</tr>
</tbody>
</table>

- Core business with unabated high demand in all segments; pandemic-related effects of about 26pp, acquisitions accounted for around 6pp of growth
- Pandemic-related effects on order intake a good 31pp, M&A ~9pp; increase also reflects changed ordering pattern of customers
- Underlying EBITDA margin rose significantly due to economies of scale and underproportionate cost development

---

1 Constant currencies  2 Underlying = excluding extraordinary items  3 Underlying EPS = based on net profit after non-controlling interest; adjusted for extraordinary items as well as amortization and based on a normalized financial result and normalized tax rate
High double-digit sales growth in all geographies

<table>
<thead>
<tr>
<th>Region</th>
<th>€ in millions</th>
<th>H1 2020</th>
<th>H1 2021</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Americas</td>
<td>€ in millions</td>
<td>312.6</td>
<td>419.8</td>
<td>+46.1%</td>
</tr>
<tr>
<td>EMEA</td>
<td>€ in millions</td>
<td>340.3</td>
<td>580.1</td>
<td>+71.3%</td>
</tr>
<tr>
<td>Asia</td>
<td>Pacific</td>
<td>€ in millions</td>
<td>216.2</td>
<td>352.0</td>
</tr>
</tbody>
</table>

- Strong organic growth in the Americas
- EMEA with above average effect from vaccine manufacturing and acquisitions
- Very dynamic increase in Asia|Pacific

Acc. to customers' location; growth in constant currencies

Sales by Region in %

- EMEA ~43%
- Americas ~31%
- Asia|Pacific ~26%

€1,351.9m
Operating cash flow rises significantly

<table>
<thead>
<tr>
<th>Sartorius Stedim Biotech Group</th>
<th>H1 2020</th>
<th>H1 2021</th>
<th>▲ in %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Underlying EBITDA</td>
<td>262.3</td>
<td>487.4</td>
<td>+85.8</td>
</tr>
<tr>
<td>Extraordinary items</td>
<td>-13.5</td>
<td>-7.0</td>
<td>n.m.</td>
</tr>
<tr>
<td>Financial result</td>
<td>-10.5</td>
<td>-40.8</td>
<td>n.m.</td>
</tr>
<tr>
<td>Underlying net profit&lt;sup&gt;1,2&lt;/sup&gt;</td>
<td>167.4</td>
<td>321.4</td>
<td>+91.9</td>
</tr>
<tr>
<td>Reported net profit&lt;sup&gt;2&lt;/sup&gt;</td>
<td>141.1</td>
<td>258.4</td>
<td>+83.2</td>
</tr>
<tr>
<td>Operating cash flow</td>
<td>195.3</td>
<td>368.1</td>
<td>+88.5</td>
</tr>
<tr>
<td>Investing cash flow&lt;sup&gt;3&lt;/sup&gt;</td>
<td>-296.4</td>
<td>-114.5</td>
<td>n.m.</td>
</tr>
<tr>
<td>CAPEX ratio (in %)</td>
<td>5.8</td>
<td>8.4</td>
<td>+2.6pp</td>
</tr>
</tbody>
</table>

- Net operating cash flow mostly driven by higher earnings
- Extraordinary items in prior-year influenced by M&A and corporate projects
- Financial result includes valuation effect related to the earn-out liability from acquisition of BIA Separations
- Investing cash flow in prior year driven by M&A

2020 numbers adjusted due to final PPA for the acquisitions of 2020. 1 Underlying net profit = net profit adjusted for extraordinary items, amortization and based on a normalized financial result and a normalized tax rate. 2 After non-controlling interest. 3 Net cash flow from investing activities and acquisitions.
Financial indicators remain on very solid level

Key Financial Indicators

<table>
<thead>
<tr>
<th></th>
<th>Dec. 31, 2020</th>
<th>June 30, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equity ratio in %</td>
<td>48.4</td>
<td>48.1</td>
</tr>
<tr>
<td>Net debt in millions of €</td>
<td>527.3</td>
<td>355.2</td>
</tr>
<tr>
<td>Net debt</td>
<td>underlying EBITDA(^1)</td>
<td>0.8</td>
</tr>
</tbody>
</table>

1 Includes underlying pro forma EBITDA of acquisitions completed in 2020

Net Debt and Net Debt to Underlying EBITDA

- Net debt in millions of € (lhs)
- Net debt to underlying EBITDA (rhs)
Strong outlook for 2021, uncertainties remain higher than usual

<table>
<thead>
<tr>
<th>FY 2021 Guidance¹</th>
<th>[change vs. previous guidance]</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sales revenue growth</td>
</tr>
<tr>
<td>Sartorius Stedim Biotech</td>
<td>~48% [+10pp]</td>
</tr>
</tbody>
</table>

- Pandemic related demand is expected to contribute ~20pp to sales growth (previously ~18pp); M&A ~4pp (previously ~5.5pp)
- CAPEX ratio expected at ~12% due to increased sales guidance (previously ~14%; FY 2020: 8.3%)
- Net debt to underlying EBITDA: ~0.5 (previously ~0.6; FY 2020: 0.8)

¹ In constant currencies
Agenda

Overview | Strategy

Mid-term Growth Prospects

H1 2021 Results | FY 2021 Guidance

Appendix
Corporate responsibility & further financial information

To Sartorius Stedim Biotech, sustainability means operating responsibly over the long term – with respect to business partners, employees and society as well as to natural resources. Learn more about our commitment:

- SRI Presentation
- GRI Report 2020

Please click below for further financial information:
- Half-Year Report H1 2021
- Earnings Release Q1 2021
- Annual Report 2020
- Earnings Release 9M 2020
Sartorius Stedim Biotech shares – an attractive investment

- Biopharma market fueled by long-term growth drivers
- Leading market positions in key technologies and high brand awareness
- Global presence with strong base in growth regions
- High entry barriers, low price-sensitivity and consolidated competitive landscape
- Diversified revenue base and high share of recurring revenues provide low volatility
- Proven growth track record: Sales CAGR\(^1\) of ~16.5% over the last five years

\(^1\) In constant currencies
Sartorius Stedim Biotech

Share price performance

ISIN: FR0013154002
Ticker: DIM
Number of share: 92,180,190
Indices: SBF 120 | CAC Next 20 | CAC Large 60 | CAC All-Tradable | CAC All Shares | CAC Healthcare | MSCI Europe | STOXX Europe 600
Market cap.: €40.4bn (as of July 21, 2021)
A sampling of the product portfolio

Filtration

Purification

Fermentation

Fluid management
Financial calendar and contacts

- **October 20, 2021**
  Publication Nine-Month Results 2021 | Göttingen

**Petra Kirchhoff**
Head of Corporate Communications & IR
Phone: +49.551.308.1686
E-mail: petra.kirchhoff@sartorius.com

**Ben Orzelek**
Head of Investor Relations
Phone: +49.551.308.1668
E-mail: ben.orzelek@sartorius.com

Sartorius Corporate Administration GmbH
Otto-Brenner-Straße 20
37079 Göttingen, Germany